WALTHAM, Mass., Aug. 2, 2011 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that results from several studies utilizing its BGM Galectin-3™ test will be presented at the upcoming European Society of Cardiology (ESC) Congress 2011, to be held in Paris, France, August 27-31, 2011. The presentations will address four important topics related to galectin-3-mediated cardiac disease: (1) the role of galectin-3 in predicting patients' response to heart failure therapy for select drug classes; (2) the ability of galectin-3 to identify individuals at risk for cardiovascular events prior to their first diagnosis of heart failure; (3) the mechanism and role of galectin-3 in heart failure development; and (4) the opportunity to block galectin-3 using natural carbohydrate compounds and their effects on heart failure development.
